{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:04:30Z","timestamp":1761851070956,"version":"build-2065373602"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["121Z099"],"award-info":[{"award-number":["121Z099"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.molimm.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T06:30:02Z","timestamp":1758695402000},"page":"121-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic targeting of neuroinflammation in sphingolipidosis"],"prefix":"10.1016","volume":"187","author":[{"given":"Ebru","family":"Ada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-5011","authenticated-orcid":false,"given":"Volkan","family":"Seyrantepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12944-021-01466-0","article-title":"Sphingolipid lysosomal storage diseases: from bench to bedside","volume":"20","author":"Abed Rabbo","year":"2021","journal-title":"Lipids Health Dis."},{"issue":"19","key":"10.1016\/j.molimm.2025.09.005_bib2","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/hmg\/ddt250","article-title":"Deletion of tumor necrosis factor-\u03b1 ameliorates neurodegeneration in sandhoff disease mice","volume":"22","author":"Abo-ouf","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"15","key":"10.1016\/j.molimm.2025.09.005_bib3","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/AEM.00463-07","article-title":"Production of recombinant \u03b2-Hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and sandhoff diseases, in the methylotrophic yeast ogataea minuta","volume":"73","author":"Akeboshi","year":"2007","journal-title":"Appl. Environ. Microbiol."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s11064-013-0992-5","article-title":"Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile sandhoff disease mice","volume":"38","author":"Arthur","year":"2013","journal-title":"Neurochem. Res."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-Based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.molimm.2025.09.005_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2018.00488","article-title":"Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response","volume":"12","author":"Bachiller","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","article-title":"Lysosomes as dynamic regulators of cell and organismal homeostasis","volume":"21","author":"Ballabio","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"Suppl 1(0 1)","key":"10.1016\/j.molimm.2025.09.005_bib9","first-page":"72","article-title":"Gaucher disease: the metabolic defect, pathophysiology, phenotypes, and natural history","volume":"12","author":"Baris","year":"2014","journal-title":"Pediatr. Endocrinol. Rev. PER"},{"key":"10.1016\/j.molimm.2025.09.005_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/01.wnl.0000194225.78917.de","article-title":"Substrate reduction therapy in the infantile form of Tay-Sachs disease","volume":"66","author":"Bembi","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.molimm.2025.09.005_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jnc.15136","article-title":"Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of gaucher disease","volume":"156","author":"Blumenreich","year":"2021","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/diseases4040040","article-title":"Biomarkers in lysosomal storage diseases","volume":"4","author":"Bobillo Lobato","year":"2016","journal-title":"Diseases"},{"key":"10.1016\/j.molimm.2025.09.005_bib16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79830","article-title":"Neuroinflammation in neuronopathic gaucher disease: role of microglia and NK cells, biomarkers, and response to substrate reduction therapy","volume":"11","author":"Boddupalli","year":"2022","journal-title":"ELife"},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/ijms18071450","article-title":"Mesenchymal stem\/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents","volume":"18","author":"B\u00f6rger","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molimm.2025.09.005_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2015.00417","article-title":"Neuroinflammatory paradigms in lysosomal storage diseases","volume":"9","author":"Bosch","year":"2015","journal-title":"Front. Neurosci."},{"issue":"10","key":"10.1016\/j.molimm.2025.09.005_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","article-title":"Lysosomal storage diseases\u2014the horizon expands","volume":"9","author":"Boustany","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"21","key":"10.1016\/j.molimm.2025.09.005_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib21","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3390\/ijms21072566","article-title":"Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease","volume":"21","author":"Breiden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1471-4159.2004.02457.x","article-title":"Phospholipid synthesis is decreased in neuronal tissue in a mouse model of sandhoff disease","volume":"90","author":"Buccoliero","year":"2004","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095023","article-title":"Evidence for aberrant astrocyte hemichannel activity in juvenile neuronal ceroid lipofuscinosis (JNCL)","volume":"9","author":"Burkovetskaya","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1566523218666180404162622","article-title":"Genetics and therapies for GM2 gangliosidosis","volume":"18","author":"Cachon-Gonzalez","year":"2018","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.molimm.2025.09.005_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.892248","article-title":"Analysis of brain lipids in the early-onset Tay\u2013Sachs disease mouse model with the combined deficiency of \u03b2-Hexosaminidase a and Neuraminidase 3","volume":"9","author":"Can","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/cge.13999","article-title":"Current and experimental therapeutics for fabry disease","volume":"100","author":"Castelli","year":"2021","journal-title":"Clin. Genet."},{"key":"10.1016\/j.molimm.2025.09.005_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nbd.2018.12.007","article-title":"Cinnamic acid activates PPAR\u03b1 to stimulate lysosomal biogenesis and lower amyloid plaque pathology in an Alzheimer\u2019s disease mouse model","volume":"124","author":"Chandra","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.molimm.2025.09.005_bib28","first-page":"1221.e1","article-title":"Evaluation of proinflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can. J. Cardiol."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12781","article-title":"The role of astrocytes in oxidative stress of central nervous system: a mixed blessing","volume":"53","author":"Chen","year":"2020","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay\u2013Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.molimm.2025.09.005_bib31","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1800165115","article-title":"Normal aging induces A1-like astrocyte reactivity","volume":"115","author":"Clarke","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.molimm.2025.09.005_bib32","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","article-title":"Cln3 Deltaex7\/8 knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth","volume":"11","author":"Cotman","year":"2002","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217780","article-title":"Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: fabry and gaucher disease","volume":"14","author":"Crivaro","year":"2019","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1073858418809941","article-title":"Astrocytes: heterogeneous and dynamic phenotypes in neurodegeneration and innate immunity","volume":"25","author":"Cunningham","year":"2019","journal-title":"Neuroscientist"},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/acn3.306","article-title":"Efficacy and ototoxicity of different cyclodextrins in Niemann\u2013Pick C disease","volume":"3","author":"Davidson","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","article-title":"Diagnosing neuronopathic gaucher disease: new considerations and challenges in assigning gaucher phenotypes","volume":"132","author":"Daykin","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12974-020-01947-6","article-title":"GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease","volume":"17","author":"Demir","year":"2020","journal-title":"J. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.molimm.2025.09.005_bib39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.4103\/1673-5374.306064","article-title":"Astrocytes: a double-edged sword in neurodegenerative diseases","volume":"16","author":"Ding","year":"2021","journal-title":"Neural Regen. Res."},{"issue":"S2","key":"10.1016\/j.molimm.2025.09.005_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/103.3.695","article-title":"Hereditary leucodystrophy in the mouse: the new mutant twitcher","volume":"103","author":"Duchen","year":"1980","journal-title":"Brain"},{"issue":"44","key":"10.1016\/j.molimm.2025.09.005_bib42","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"20","key":"10.1016\/j.molimm.2025.09.005_bib43","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe\u2019s disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2017.05.015","article-title":"Psychosine, a marker of krabbe phenotype and treatment effect","volume":"121","author":"Escolar","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","article-title":"Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic gaucher disease","volume":"20","author":"Farfel-Becker","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.008185","article-title":"Animal models for gaucher disease research","volume":"4","author":"Farfel-Becker","year":"2011","journal-title":"Dis. Models Mech."},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib47","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.ymthe.2024.05.019","article-title":"Perinatal loss of galactosylceramidase in both oligodendrocytes and microglia is crucial for the pathogenesis of krabbe disease in mice","volume":"32","author":"Favret","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82927-1","article-title":"Ablation of lipocalin-2 reduces neuroinflammation in a mouse model of krabbe disease","volume":"14","author":"Favret","year":"2024","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.molimm.2025.09.005_bib49","first-page":"1","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl. Sci. Rare Dis."},{"issue":"10","key":"10.1016\/j.molimm.2025.09.005_bib50","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.3390\/ijms23105842","article-title":"Neuropathological features of gaucher disease and Gaucher disease with Parkinsonism","volume":"23","author":"Furderer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2016.08.024","article-title":"Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease","volume":"66","author":"Gariani","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","article-title":"Consensus clinical management guidelines for Niemann-Pick disease type C","volume":"13","author":"Geberhiwot","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"01","key":"10.1016\/j.molimm.2025.09.005_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic leukodystrophy \u2013 an update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics"},{"issue":"1\u20132","key":"10.1016\/j.molimm.2025.09.005_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2014.07.012","article-title":"Neuroimmune regulation of microglial activity is involved in neuroinflammation and neurodegenerative diseases","volume":"274","author":"Gonz\u00e1lez","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"9645","key":"10.1016\/j.molimm.2025.09.005_bib55","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.spen.2017.08.005","article-title":"Overview of inflammation in neurometabolic diseases","volume":"24","author":"Grabowski","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2014.09.046","article-title":"History, genetic, and recent advances on krabbe disease","volume":"555","author":"Graziano","year":"2015","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41581-023-00692-2","article-title":"The role of lysosomes in metabolic and autoimmune diseases","volume":"19","author":"Gros","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0022-510X(97)00299-2","article-title":"Adult Sandhoff\u2019s disease: R505Q and I207V substitutions in the HEXB gene of the first Japanese case","volume":"155","author":"Hara","year":"1998","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1471-4906(01)02154-8","article-title":"Prostaglandins as modulators of immunity","volume":"23","author":"Harris","year":"2002","journal-title":"Trends Immunol."},{"issue":"R1","key":"10.1016\/j.molimm.2025.09.005_bib61","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1093\/hmg\/ddr112","article-title":"Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?","volume":"20","author":"Hawkins-Salsbury","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"16","key":"10.1016\/j.molimm.2025.09.005_bib62","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.4199-14.2015","article-title":"Mechanism-Based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy","volume":"35","author":"Hawkins-Salsbury","year":"2015","journal-title":"J. Neurosci."},{"issue":"25","key":"10.1016\/j.molimm.2025.09.005_bib63","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","article-title":"Phenotype of arylsulfatase A-deficient mice: relationship to human\u2009metachromatic\u2009leukodystrophy","volume":"93","author":"Hess","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molimm.2025.09.005_bib64","article-title":"Successful implementation of classical ketogenic dietary therapy in a patient with Niemann-Pick disease type c","volume":"27","author":"H\u00f6ller","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3346\/jkms.2006.21.4.733","article-title":"Upregulation of proinflammatory cytokines in the fetal brain of the gaucher mouse","volume":"21","author":"Hong","year":"2006","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.molimm.2025.09.005_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2016.08.008","article-title":"Bi-phasic gliosis drives neuropathology in a sandhoff disease mouse model","volume":"299","author":"Hooper","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.molimm.2025.09.005_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddw422","article-title":"Neuronal pentraxin 1 depletion delays neurodegeneration and extends life in sandhoff disease mice","author":"Hooper","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib68","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s00415-024-12439-5","article-title":"Neurological symptoms in adults with gaucher disease: a systematic review","volume":"271","author":"Imbalzano","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11011-025-01553-6","article-title":"Combined treatment of ketogenic diet and propagermanium reduces neuroinflammation in Tay-Sachs disease mouse model","volume":"40","author":"Inci","year":"2025","journal-title":"Metab. Brain Dis."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib70","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant \u03b1-galactosidase a in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"10.1016\/j.molimm.2025.09.005_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2017.00024","article-title":"Glial cells and their function in the adult brain: a journey through the history of their ablation","volume":"11","author":"J\u00e4kel","year":"2017","journal-title":"Front. Cell. Neurosci."},{"issue":"8","key":"10.1016\/j.molimm.2025.09.005_bib72","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s11064-012-0781-6","article-title":"Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome Proliferator-Activated receptor \u03b2","volume":"37","author":"Jana","year":"2012","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib73","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: mapping a timeline of clinical changes","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.molimm.2025.09.005_bib74","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in sandhoff disease mice treated with n -butyldeoxynojirimycin","volume":"96","author":"Jeyakumar","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib75","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm_00000246","article-title":"Expression of genes and their responses to enzyme replacement therapy in a fabry disease mouse model","volume":"24","author":"Jung","year":"2009","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12974-022-02408-y","article-title":"Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics","volume":"19","author":"Kamma","year":"2022","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jnr.20525","article-title":"Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis","volume":"81","author":"Kauppinen","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.molimm.2025.09.005_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156974","article-title":"A comprehensive review: neuroinflammation and immune communication between the central nervous system and the periphery","volume":"192","author":"Kaur","year":"2025","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016269","article-title":"Prostaglandin E2 reverses aberrant production of an inflammatory chemokine by microglia from sandhoff disease model mice through the cAMP-PKA pathway","volume":"6","author":"Kawashita","year":"2011","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib80","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type associated with restricting the development of Alzheimer\u2019s disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12987-022-00367-3","article-title":"The effect of A1 and A2 reactive astrocyte expression on hydrocephalus shunt failure","volume":"19","author":"Khodadadei","year":"2022","journal-title":"Fluids Barriers CNS"},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib82","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/emm.2006.41","article-title":"Downregulation of neurotrophic factors in the brain of a mouse model of gaucher disease: implications for neuronal loss in gaucher disease","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.molimm.2025.09.005_bib83","article-title":"The juvenile gangliosidoses: a timeline of clinical change","volume":"25","author":"King","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"355","key":"10.1016\/j.molimm.2025.09.005_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9823","article-title":"Heat shock protein\u2013based therapy as a potential candidate for treating the sphingolipidoses","volume":"8","author":"Kirkegaard","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib85","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.4049\/jimmunol.134.3.1810","article-title":"Activation of the alternative pathway of complement by human peripheral nerve myelin","volume":"134","author":"Koski","year":"1985","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib86","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13023-020-01489-3","article-title":"Natural history of krabbe disease \u2013 a nationwide study in Germany using clinical and MRI data","volume":"15","author":"Krieg","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.molimm.2025.09.005_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1420067","article-title":"Inflammation in fabry disease: stages, molecular pathways, and therapeutic implications","volume":"11","author":"Kurdi","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1517\/13543784.10.3.455","article-title":"Substrate reduction therapy for glycosphingolipid storage disorders","volume":"10","author":"Lachmann","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.molimm.2025.09.005_bib89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S85354","article-title":"Animal models of GM2 gangliosidosis: utility and limitations","volume":"9","author":"Lawson","year":"2016","journal-title":"Appl. Clin. Genet."},{"issue":"17","key":"10.1016\/j.molimm.2025.09.005_bib90","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib91","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1073\/pnas.61.2.484","article-title":"The fine structure of the cerebroside occurring in Gaucher\u2019s disease","volume":"61","author":"Lee","year":"1968","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.molimm.2025.09.005_bib92","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s11255-024-04042-4","article-title":"Fabry disease: a rare disorder calling for personalized medicine","volume":"56","author":"Lerario","year":"2024","journal-title":"Int. Urol. Nephrol."},{"issue":"7638","key":"10.1016\/j.molimm.2025.09.005_bib93","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib94","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/cells12070993","article-title":"Rapamycin alleviates protein aggregates, reduces neuroinflammation, and rescues demyelination in globoid cell leukodystrophy","volume":"12","author":"Lin","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib95","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12031-019-01409-6","article-title":"Clinical and molecular characteristics of two Chinese children with infantile sandhoff disease and review of the literature","volume":"70","author":"Liu","year":"2020","journal-title":"J. Mol. Neurosci."},{"issue":"11","key":"10.1016\/j.molimm.2025.09.005_bib96","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"Lloyd-Evans","year":"2008","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101757","article-title":"Neonatal cholestasis and Niemann-Pick type C disease: a literature review","volume":"45","author":"L\u00f3pez de Frutos","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/mgme.2001.3194","article-title":"Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe Disease)","volume":"73","author":"Luzi","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molimm.2025.09.005_bib99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainres.2009.09.017","article-title":"Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy","volume":"1300","author":"Luzi","year":"2009","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40364-024-00624-7","article-title":"The role of macrophage plasticity in neurodegenerative diseases","volume":"12","author":"Ma","year":"2024","journal-title":"Biomark. Res."},{"issue":"12","key":"10.1016\/j.molimm.2025.09.005_bib101","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for Late-onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molimm.2025.09.005_bib102","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S424622","article-title":"Globoid cell leukodystrophy (Krabbe Disease): an update","volume":"12","author":"Maghazachi","year":"2023","journal-title":"ImmunoTargets Ther."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib103","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.xkme.2021.01.006","article-title":"Lupus nephritis and hydroxychloroquine-associated zebra bodies: not just in fabry disease","volume":"3","author":"Manabe","year":"2021","journal-title":"Kidney Med."},{"key":"10.1016\/j.molimm.2025.09.005_bib104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2015.04.020","article-title":"Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy","volume":"271","author":"Matthes","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.molimm.2025.09.005_bib105","first-page":"1","author":"Mauhin","year":"2015","journal-title":"Innate and Adaptive Immune Response in Fabry Disease"},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib106","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cancers14030687","article-title":"Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases","volume":"14","author":"Mekhaeil","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib107","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11481-023-10092-9","article-title":"Elucidating the therapeutic utility of olaparib in sulfatide-induced human astrocyte toxicity and neuroinflammation","volume":"18","author":"Mekhaeil","year":"2023","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib108","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13311-023-01409-w","article-title":"Olaparib attenuates demyelination and neuroinflammation in an organotypic slice culture model of metachromatic leukodystrophy","volume":"20","author":"Mekhaeil","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","article-title":"Type 2 gaucher disease: 15 new cases and review of the literature","volume":"28","author":"Mignot","year":"2006","journal-title":"Brain Dev."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","article-title":"Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses","volume":"6","author":"Mole","year":"2005","journal-title":"Neurogenetics"},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib111","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ymgme.2012.01.020","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann\u2013Pick C mice","volume":"105","author":"Nietupski","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molimm.2025.09.005_bib112","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nbd.2018.07.014","article-title":"Inhibition of astrocytic adenosine receptor A2A attenuates microglial activation in a mouse model of sandhoff disease","volume":"118","author":"Ogawa","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib113","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase a deficient mice: a model of fabry\u2009disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib114","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nn.3930","article-title":"Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory","volume":"18","author":"Orr","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.molimm.2025.09.005_bib115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2017.10.014","article-title":"Istradefylline reduces memory deficits in aging mice with amyloid pathology","volume":"110","author":"Orr","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"48","key":"10.1016\/j.molimm.2025.09.005_bib116","doi-asserted-by":"crossref","first-page":"45984","DOI":"10.1074\/jbc.M200250200","article-title":"Gemfibrozil, a Lipid-lowering drug, inhibits the induction of Nitric-oxide synthase in human astrocytes","volume":"277","author":"Pahan","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib117","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1570159X20666220601124117","article-title":"Fabry disease: current and novel therapeutic strategies. A narrative review","volume":"21","author":"Palaiodimou","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.molimm.2025.09.005_bib118","first-page":"557","author":"Pastores","year":"2023","journal-title":"Lysosomal storage disorders: Clinical and therapeutic aspects"},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib119","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1152\/physrev.00041.2013","article-title":"Astrocyte reactivity and reactive astrogliosis: costs and benefits","volume":"94","author":"Pekny","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molimm.2025.09.005_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.906647","article-title":"Therapeutic strategies for Tay-Sachs disease","volume":"13","author":"Picache","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib121","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib122","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1042\/BST20220711","article-title":"The expanding boundaries of sphingolipid lysosomal storage diseases; insights from Niemann\u2013Pick disease type C","volume":"51","author":"Platt","year":"2023","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib123","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"Lysosomal storage disorders: the cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.molimm.2025.09.005_bib124","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/jnr.23804","article-title":"Neuroimmune mechanisms in <scp>K<\/scp> rabbe\u2019s disease","volume":"94","author":"Potter","year":"2016","journal-title":"J. Neurosci. Res."},{"issue":"17","key":"10.1016\/j.molimm.2025.09.005_bib125","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1093\/hmg\/ddt190","article-title":"Missense mutation in mouse GALC mimics human gene defect and offers new insights into krabbe disease","volume":"22","author":"Potter","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib126","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-immunol-093019-110159","article-title":"Microglia and central nervous system\u2013associated macrophages\u2014from origin to disease modulation","volume":"39","author":"Prinz","year":"2021","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib127","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/14084","article-title":"Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases","volume":"1","author":"Puri","year":"1999","journal-title":"Nat. Cell Biol."},{"issue":"17","key":"10.1016\/j.molimm.2025.09.005_bib128","doi-asserted-by":"crossref","first-page":"13620","DOI":"10.1074\/jbc.M111.304857","article-title":"Neutral sphingomyelinase 2 deficiency increases hyaluronan synthesis by up-regulation of hyaluronan synthase 2 through decreased ceramide production and activation of akt","volume":"287","author":"Qin","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.molimm.2025.09.005_bib129","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.3390\/cells12242791","article-title":"Lipid-lowering drug gemfibrozil protects mice from Tay-Sachs disease via peroxisome proliferator-activated receptor \u03b1","volume":"12","author":"Raha","year":"2023","journal-title":"Cells"},{"issue":"35","key":"10.1016\/j.molimm.2025.09.005_bib130","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1523\/JNEUROSCI.2287-07.2007","article-title":"Increasing sulfatide synthesis in Myelin-Forming cells of arylsulfatase A-Deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy","volume":"27","author":"Ramakrishnan","year":"2007","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib131","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.beem.2014.10.001","article-title":"Metachromatic leukodystrophy: disease spectrum and approaches for treatment","volume":"29","author":"van Rappard","year":"2015","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.molimm.2025.09.005_bib133","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/iub.257","article-title":"Fabry disease: treatment and diagnosis","volume":"61","author":"Rozenfeld","year":"2009","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib134","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","article-title":"PARP inhibition in cancer: an update on clinical development","volume":"14","author":"Sachdev","year":"2019","journal-title":"Target. Oncol."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib135","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay\u2013Sachs and sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"issue":"21","key":"10.1016\/j.molimm.2025.09.005_bib136","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1093\/hmg\/dds313","article-title":"The galactocerebrosidase enzyme contributes to maintain a functional neurogenic niche during early post-natal CNS development","volume":"21","author":"Santambrogio","year":"2012","journal-title":"Hum. Mol. Genet."},{"issue":"23","key":"10.1016\/j.molimm.2025.09.005_bib137","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.3390\/ijms20235897","article-title":"Advances in sphingolipidoses: CRISPR-Cas9 editing as an option for modelling and therapy","volume":"20","author":"Santos","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib138","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1212\/WNL.49.5.1392","article-title":"Adult-onset krabbe disease with homozygous T1853C mutation in the galactocerebrosidase gene","volume":"49","author":"Satoh","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib139","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.cell.2018.07.028","article-title":"Molecular diversity and specializations among the cells of the adult mouse brain","volume":"174","author":"Saunders","year":"2018","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib141","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/jpet.103.063214","article-title":"The therapeutic effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide.HCl], a selective inhibitor of Poly(ADP-Ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation","volume":"310","author":"Scott","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib142","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ptr.5304","article-title":"Therapeutic potential of resveratrol in type I gaucher disease","volume":"29","author":"Seo","year":"2015","journal-title":"Phytother. Res."},{"key":"10.1016\/j.molimm.2025.09.005_bib143","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.expneurol.2017.09.012","article-title":"Murine sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease","volume":"299","author":"Seyrantepe","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.molimm.2025.09.005_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.576221","article-title":"Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches","volume":"7","author":"Shaimardanova","year":"2020","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib145","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.3390\/ijms24043627","article-title":"Gene therapy of sphingolipid metabolic disorders","volume":"24","author":"Shaimardanova","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib146","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-5793(97)01263-5","article-title":"Generation and characterization of transgenic mice expressing a human mutant \u03b1-galactosidase with an R301Q substitution causing a variant form of fabry disease","volume":"417","author":"Shimmoto","year":"1997","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib147","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.arcmed.2021.05.001","article-title":"Gaucher disease: identification and novel variants in Mexican and spanish patients","volume":"52","author":"Silva Garc\u00eda","year":"2021","journal-title":"Arch. Med. Res."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib148","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nbd.2009.07.010","article-title":"Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1","volume":"36","author":"Smith","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ajpath.2013.10.011","article-title":"Innate immune activation in the pathogenesis of a murine model of globoid cell leukodystrophy","volume":"184","author":"Snook","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molimm.2025.09.005_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01663","article-title":"New approaches to Tay-Sachs disease therapy","volume":"9","author":"Solovyeva","year":"2018","journal-title":"Front. Physiol."},{"issue":"11","key":"10.1016\/j.molimm.2025.09.005_bib151","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/cells11111730","article-title":"Dysregulation of immune response mediators and Pain-Related ion channels is associated with Pain-like behavior in the GLA KO mouse model of fabry disease","volume":"11","author":"Spitzel","year":"2022","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.molimm.2025.09.005_bib152","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3390\/cells11132021","article-title":"Single-cell RNA-sequencing: astrocyte and microglial heterogeneity in health and disease","volume":"11","author":"Spurgat","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib153","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/mt.2015.69","article-title":"Anti-inflammatory therapy with simvastatin improves neuroinflammation and CNS function in a mouse model of metachromatic leukodystrophy","volume":"23","author":"Stein","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib154","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"the French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12974-024-03059-x","article-title":"Border-associated macrophages in the central nervous system","volume":"21","author":"Sun","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.molimm.2025.09.005_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.903455","article-title":"Inflammation from peripheral organs to the brain: how does systemic inflammation cause neuroinflammation?","volume":"14","author":"Sun","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.molimm.2025.09.005_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578573","article-title":"Neuroimmunology in globoid cell leukodystrophy: a comprehensive review including treatments, models, and neuroimmune mechanisms underlying neuropathology","volume":"402","author":"Sutter","year":"2025","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib158","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF00309622","article-title":"Neuropathology of mice with targeted disruption of the hexa gene, a model of Tay-Sachs disease","volume":"89","author":"Taniike","year":"1995","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.molimm.2025.09.005_bib159","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1023\/B:NERE.0000021232.05175.38","article-title":"Lysosomal storage diseases: is impaired apoptosis a pathogenic mechanism?","volume":"29","author":"Tardy","year":"2004","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib160","doi-asserted-by":"crossref","DOI":"10.1038\/srep24579","article-title":"Cerebral spinal fluid levels of cytokines are elevated in patients with metachromatic leukodystrophy","volume":"6","author":"Thibert","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2025.09.005_bib161","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.arr.2014.11.003","article-title":"DAMPs and neurodegeneration","volume":"24","author":"Thundyil","year":"2015","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.molimm.2025.09.005_bib162","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis","volume":"69","author":"Tsuji","year":"2011","journal-title":"Ann. Neurol."},{"issue":"6377","key":"10.1016\/j.molimm.2025.09.005_bib163","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher\u2019s disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.molimm.2025.09.005_bib164","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/hmg\/ddq204","article-title":"Saposin c mutations in gaucher disease patients resulting in lysosomal lipid accumulation, saposin c deficiency, but normal prosaposin processing and sorting","volume":"19","author":"Vaccaro","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.molimm.2025.09.005_bib165","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.3390\/ijms24098434","article-title":"Functions of astrocytes under normal conditions and after a brain disease","volume":"24","author":"Valles","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.molimm.2025.09.005_bib166","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/biomedicines9121864","article-title":"Anti-Inflammatory mesenchymal stromal cell-derived extracellular vesicles improve pathology in Niemann\u2013Pick type C disease","volume":"9","author":"Van Hoecke","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib167","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/1073858413510208","article-title":"Astrogliopathology","volume":"20","author":"Verkhratsky","year":"2014","journal-title":"Neuroscientist"},{"issue":"27","key":"10.1016\/j.molimm.2025.09.005_bib168","doi-asserted-by":"crossref","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","article-title":"Common and uncommon pathogenic cascades in lysosomal storage diseases","volume":"285","author":"Vitner","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib169","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm.3449","article-title":"RIPK3 as a potential therapeutic target for Gaucher\u2019s disease","volume":"20","author":"Vitner","year":"2014","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.molimm.2025.09.005_bib170","doi-asserted-by":"crossref","first-page":"26167","DOI":"10.1074\/jbc.M311591200","article-title":"Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport","volume":"279","author":"Vruchte","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.molimm.2025.09.005_bib171","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","article-title":"Microglial activation precedes acute neurodegeneration in sandhoff disease and is suppressed by bone marrow transplantation","volume":"97","author":"Wada","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molimm.2025.09.005_bib172","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbior.2018.09.013","article-title":"Sphingolipids in neurodegeneration (with focus on ceramide and S1P)","volume":"70","author":"Wang","year":"2018","journal-title":"Adv. Biol. Regul."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib173","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1038\/s41467-020-19179-w","article-title":"Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of krabbe disease","volume":"11","author":"Weinstock","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib174","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of type 2 gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.molimm.2025.09.005_bib175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2017.03.004","article-title":"Suppression of NK and CD8+ t cells reduces astrogliosis but accelerates cerebellar dysfunction and shortens life span in a mouse model of sandhoff disease","volume":"306","author":"White","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.molimm.2025.09.005_bib176","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nbd.2014.03.001","article-title":"Improved neuroprotection using miglustat, curcumin, and ibuprofen as a triple combination therapy in Niemann\u2013Pick disease type C1 mice","volume":"67","author":"Williams","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.molimm.2025.09.005_bib177","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1016\/j.molimm.2025.09.005_bib178","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2147\/TCRM.S5777","article-title":"New therapies in the management of Niemann-Pick type c disease: clinical utility of miglustat","author":"Wraith","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.molimm.2025.09.005_bib179","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.998275","article-title":"A neglected neurodegenerative disease: adult-onset globoid cell leukodystrophy","volume":"16","author":"Wu","year":"2022","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib180","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1038\/s41467-022-34420-4","article-title":"Lipidomic signatures align with inflammatory patterns and outcomes in critical illness","volume":"13","author":"Wu","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib181","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jcyt.2024.03.195","article-title":"Cord blood derived macrophages promote the proliferation of oligodendrocyte precursor cells","volume":"26","author":"Xu","year":"2024","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.molimm.2025.09.005_bib182","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1172\/JCI200419639","article-title":"Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses","volume":"113","author":"Yamaguchi","year":"2004","journal-title":"J. Clin. Investig."},{"issue":"21","key":"10.1016\/j.molimm.2025.09.005_bib183","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1073\/pnas.91.21.9975","article-title":"Targeted disruption of the hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease","volume":"91","author":"Yamanaka","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.molimm.2025.09.005_bib184","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/107999001750277862","article-title":"An Anti-Inflammatory drug, propagermanium, May target GPI-Anchored proteins associated with an MCP-1 receptor, CCR2","volume":"21","author":"Yokochi","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"issue":"16","key":"10.1016\/j.molimm.2025.09.005_bib185","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0960-9822(01)00396-7","article-title":"Critical role for glycosphingolipids in Niemann-Pick disease type C","volume":"11","author":"Zervas","year":"2001","journal-title":"Curr. Biol."},{"issue":"7","key":"10.1016\/j.molimm.2025.09.005_bib186","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049995","article-title":"A zebrafish model of combined saposin deficiency identifies acid sphingomyelinase as a potential therapeutic target","volume":"16","author":"Zhang","year":"2023","journal-title":"Dis. Models Mech."},{"issue":"1","key":"10.1016\/j.molimm.2025.09.005_bib187","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-021-01087-1","article-title":"Role of lysosomes in physiological activities, diseases, and therapy","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molimm.2025.09.005_bib188","doi-asserted-by":"crossref","DOI":"10.20517\/2347-8659.2018.52","article-title":"Microglial activation and polarization after subarachnoid hemorrhage","volume":"2019","author":"Zheng","year":"2019","journal-title":"Neuroimmunol. Neuroinflamm."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025002299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025002299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:59:32Z","timestamp":1761850772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589025002299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":188,"alternative-id":["S0161589025002299"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2025.09.005","relation":{},"ISSN":["0161-5890"],"issn-type":[{"type":"print","value":"0161-5890"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of neuroinflammation in sphingolipidosis","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}